overall survival in patients with chl who progress after autosct in the era of novel agents
Published 1 year ago • 54 plays • Length 4:32Download video MP4
Download video MP3
Similar videos
-
3:54
an insight into how novel agents are influencing survival outcomes in patients with mf
-
0:49
extending survival in patients with cll: novel agents, mrd, and overcoming rt
-
1:16
predictors of long-term survival in patients with dlbcl/hgbcl following autosct
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:41
acute myeloid leukemia survival rate and outlook
-
6:49
kaplan meier survival analysis
-
2:10
cancer basics – how chemotherapy works
-
1:31
overall survival of patients following treatment with luspatercept in the medalist trial
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:15
overall survival data from the pollux trial: drd versus rd in patients with r/r multiple myeloma
-
1:58
impact of checkpoint inhibitor-based salvage regimens prior to allosct in r/r chl
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
1:15
primary overall survival analysis of the zuma-7 trial
-
2:23
patient selection for autosct in hl & increasing cr rate before autosct with novel salvage regimens
-
1:08
zuma-7: overall survival benefit of axi-cel over soc in second-line lbcl
-
2:56
early vs. deferred transplantation in al amyloidosis
-
1:48
overall survival by idh2 mutant allele in late-stage r/r aml patients enrolled in idhentify
-
3:30
clinical value of event-free survival in aml
-
2:07
the microbiota: a new player in gvhd pathophysiology
-
0:56
real-world survival in patients with mixed phenotype attr-cm treated with tafamidis